Heartflow, Inc. (HTFL) Stock
6 of the hedge funds AlphaScala tracks reported HTFL in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Point72's at $50.50M. Company insiders reported 0 open-market buys and 17 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own HTFL?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 1.72M | $50.50M | +220% |
| Millennium Management Israel Englander | 923K | $27.08M | -16% |
| Citadel Ken Griffin | 800K | $23.47M | +6% |
| Renaissance Technologies Jim Simons (founder) | 383K | $11.23M | NEW |
| D.E. Shaw David Shaw | 9K | $254.7K | NEW |
| Blackstone | 8K | $224.7K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Heartflow, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 12, 26 | Farquhar John C.M. | Chief Executive Officer | SELL | 38.9K | $1.9M |
| Sep 18, 26 | Verghese Vikram | Chief Financial Officer | SELL | 16.8K | $851K |
| Sep 18, 26 | Rogers Campbell | Chief Medical Officer | SELL | 19.7K | $987K |
| Sep 17, 26 | Verghese Vikram | Chief Financial Officer | SELL | 7.6K | $380K |
| Sep 15, 26 | Verghese Vikram | Chief Financial Officer | SELL | 668 | $33K |
| Sep 14, 26 | Verghese Vikram | Chief Financial Officer | SELL | 4.6K | $231K |
| Sep 11, 26 | Farquhar John C.M. | Chief Executive Officer | SELL | 3.9K | $195K |
| Sep 11, 26 | Verghese Vikram | Chief Financial Officer | SELL | 29.7K | $1.5M |
| Sep 10, 26 | Farquhar John C.M. | Chief Executive Officer | SELL | 35.0K | $1.6M |
| Sep 8, 26 | Verghese Vikram | Chief Financial Officer | SELL | 6.6K | $332K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →HTFL price chart
Powered by TradingViewWhat does Heartflow, Inc. do?
HeartFlow, Inc. is a medical technology company specializing in precision heart care through advanced AI-powered software solutions. It transforms coronary computed tomography angiography (CCTA) scans into detailed 3D models of patients' coronary arteries, enabling non-invasive assessment of coronary artery disease (CAD). Key products include Roadmap Analysis for efficient CAD detection, FFRCT Analysis to evaluate blood flow and revascularization needs, and Plaque Analysis to quantify and characterize plaque for risk assessment and disease management. The integrated HeartFlow One platform supports clinicians in identifying, deciding, and managing CAD, optimizing patient care pathways with personalized insights. HeartFlow also provides comprehensive support services, including clinical, operational, technical, and financial resources to help institutions build scalable CCTA programs. Headquartered in Redwood City, California, the company plays a pivotal role in advancing proactive, patient-centered coronary care by empowering healthcare providers with innovative tools to detect, understand, and treat CAD effectively.